KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Account Payables: 2010-2025

Historic Change in Account Payables for Acadia Pharmaceuticals (ACAD) over the last 15 years, with Sep 2025 value amounting to $1.6 million.

  • Acadia Pharmaceuticals' Change in Account Payables rose 305.99% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 60.63%. This contributed to the annual value of -$1.4 million for FY2024, which is 128.16% down from last year.
  • Acadia Pharmaceuticals' Change in Account Payables amounted to $1.6 million in Q3 2025, which was down 17.58% from $2.0 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Change in Account Payables' 5-year high stood at $5.2 million during Q4 2023, with a 5-year trough of -$6.5 million in Q3 2023.
  • Over the past 3 years, Acadia Pharmaceuticals' median Change in Account Payables value was $1.6 million (recorded in 2025), while the average stood at $818,273.
  • In the last 5 years, Acadia Pharmaceuticals' Change in Account Payables surged by 993.26% in 2022 and then crashed by 252.17% in 2023.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Change in Account Payables stood at -$846,000 in 2021, then soared by 423.64% to $2.7 million in 2022, then soared by 91.12% to $5.2 million in 2023, then crashed by 155.21% to -$2.9 million in 2024, then soared by 305.99% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $2.0 million for Q2 2025, and $1.9 million during Q1 2025.